Development of an HPLC method for monitoring of Photofrin II therapy.

[1]  B. Ertl-Wagner,et al.  Porphyrins as radiosensitizing agents for solid neoplasms. , 2003, Current pharmaceutical design.

[2]  B. Ertl-Wagner,et al.  Application of Photofrin II as a specific radiosensitising agent in patients with bladder cancer—a report of two cases , 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[3]  G. Jori,et al.  On the double role of Photofrin as a photo- and a radio-sensitising agent: a possible new combination therapy for tumours , 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[4]  G. Jori,et al.  Photofrin as a specific radiosensitizing agent for tumors: studies in comparison to other porphyrins, in an experimental in vivo model. , 2002, Journal of photochemistry and photobiology. B, Biology.

[5]  G. Jori,et al.  Photofrin II as an Efficient Radiosensitizing Agent in an Experimental Tumor , 2001, Oncology Research and Treatment.

[6]  Thomas J. Dougherty,et al.  Basic principles of photodynamic therapy , 2001 .

[7]  A. Giatromanolaki,et al.  Outcome of patients receiving photodynamic therapy for early esophageal cancer. , 2000, International journal of radiation oncology, biology, physics.

[8]  T. Dougherty,et al.  An Assay for the Quantitation of Photofrin in Tissues and Fluids , 1997, Photochemistry and photobiology.

[9]  G. Jori,et al.  Tumour photosensitizers: approaches to enhance the selectivity and efficiency of photodynamic therapy. , 1996, Journal of photochemistry and photobiology. B, Biology.

[10]  Z. Malik,et al.  A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model. , 1996, British Journal of Cancer.

[11]  C. Foote.  DEFINITION OF TYPE I and TYPE II PHOTOSENSITIZED OXIDATION , 1991, Photochemistry and photobiology.

[12]  T. Dougherty,et al.  ACTIVITY AND PHYSICOCHEMICAL PROPERTIES OF PHOTOFRIN® , 1991, Photochemistry and photobiology.

[13]  A. Peracchia,et al.  Oesophageal cancer treated by photodynamic therapy alone or followed by radiation therapy. , 1990, Journal of photochemistry and photobiology. B, Biology.

[14]  C. Byrne,et al.  The composition of Photofrin II. , 1990, Journal of photochemistry and photobiology. B, Biology.

[15]  T J Dougherty,et al.  STUDIES ON THE STRUCTURE OF PORPHYRINS CONTAINED IN PHOTOFRIN® II , 1987, Photochemistry and photobiology.

[16]  Douglas C. Miller,et al.  The interaction of hematoporphyrin derivative, light, and ionizing radiation in a rat glioma model , 1986, Cancer.

[17]  L. Cohen,et al.  Modification of radiosensitivity by porphyrins. II. Transplanted rhabdomyosarcoma in mice. , 1966, Cancer research.

[18]  Michele T. Cooper,et al.  Cutaneous phototoxic occurrences in patients receiving Photofrin® , 1990, Lasers in surgery and medicine.

[19]  M. Berns,et al.  Spectroscopic, morphologic, and cytotoxic studies on major fractions of hematoporphyrin derivative and Photofrin II , 1987, Lasers in surgery and medicine.